Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axicabtagene ciloleucel versus standard of care in relapsed/refractory follicular lymphoma
2021-003260-28Phase 3Active
- Sponsor
- Kite Pharma
- Start
- Mar 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in follicular lymphoma (FL) comparing Axicabtagene ciloleucel with Standard of care therapy (2 arms). Primary endpoint: Progression-free survival. Started Mar 2022; status: active.
02
Drugs
axicabtagene ciloleucel
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2021-003260-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003260-28.